Cancer Diagnosis by Multiplex Protein Epitope Profiling

Informazioni relative al progetto

CANDLE

ID dell’accordo di sovvenzione: 697211

DOI

10.3030/697211

Progetto chiuso

Data della firma CE 26 Agosto 2015

Data di avvio 1 Settembre 2015

Data di completamento 31 Ottobre 2015

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

BIOSYSTEMS INTERNATIONAL KUTATO-, FEJLESZTO-, HASZNOSITO ES SZOLGALTATO KFT
Hungary

Periodic Reporting for period 1 - CANDLE (Cancer Diagnosis by Multiplex Protein Epitope Profiling)

Periodo di rendicontazione: 2015-09-01 al 2015-10-31

Sintesi del contesto e degli obiettivi generali del progetto

Cancer incidence is continuously increasing, making it a major concern of European governments. Cheaper, more sensitive and specific diagnostic tests are needed to foster early cancer diagnosis, thereby alleviating the impact of cancer on citizens’ lives and reducing overall cancer care costs. Biosystems International Kft. (BSI) developed a diagnostics technology based on plasma protein epitome biomarker panels, with promising results to meet these needs for breast (BC) and colon (CC) cancers. BSI’s novel biomarkers-based in vitro diagnostics will bring better health outcomes for the patient as earlier detection will increase survival and will reduce overall care costs contributing to the sustainability of the health care system.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

In Phase I of CANDLE, BSI consolidated the business plan incorporating thorough market and commercialization studies for BC and CC and conducted a technology intellectual property evaluation. In order to execute the plan in Phase II, BSI recruited the critical experts and stakeholders and obtained expert opinions and intents for the design and development to complete clinical validation of the biomarker panels for BC and CC. The two cancers together represent 26.8 % of all cancer incidences in the EU. Clinically validated results obtained in CANDLE will enable BSI to seize the business opportunity and to maximize return on investments through higher royalties.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

BSI will develop blood tests that could become blockbusters in the BC and CC diagnostic markets. The optimal expected impact of successful early diagnostics (screening) in CC and BC is the reduction of mortality and increase in cancer-free survival. Based on our projections the increase in five-year survival could reach 5-20 % depending on the cancer type.

bsi-graphics.jpg